No disease-modifying treatment for MCI exists yet, but efforts within the last decades have aimed at developing pharmacological therapies targeted at reducing cortical amyloid-þ (Aþ) and tau pathology, which are believed to be key in the pathogenesis of AD [10]. This evidence concerns the gene MAPT and Alzheimer disease.